05/26/2026
CAR-T cell immunotherapy has transformed treatment for blood cancers, but it has largely failed against solid tumors like lung, breast, and kidney cancer. Bouvé researcher Stephen Hatfield is working to change that.
His lab used a precise gene-editing technique called base editing to engineer CAR-T cells that can resist the immune-suppressive environment inside solid tumors, achieving complete tumor elimination in mouse models. The approach could also make treatments available "off-the-shelf," cutting the months-long wait patients currently face while their own cells are harvested and engineered.
The research, published in Nature Communications, represents a meaningful step toward bringing this therapy into human clinical trials.
➡️ https://news.northeastern.edu/2026/04/09/time-saving-cancer-treatment/
New research shows how to remove obstacles to solid tumor cancer treatments with genetic engineering.